CONTENTS


Contents


5. 6.


Chapter 1: Clinical Development in Oncology


More Narrowly Defined Target Patient Populations Contributing to Protocol Amendments in Oncology Clinical Trials


9. 12. 15. 16. 17. 19.


21. 22.


Project Optimus: helping or hindering cancer drug development?


Application of AI and ML in Pharma and Biotechnology


Oncology leads trials for 2023 with more than 52% of trials in Phase II


US launches campaign to address racial disparities in lung cancer biomarker testing


FDA committee proposes overhaul of perioperative lung cancer trials


Artificial intelligence identified two evolutionary pathways of prostate cancer


Chapter 2: Immunotherapy


CAR-T therapies and cancer risk: No easy answers for the FDA


42. 43.


Advisory board Suppliers’ directory


25.


Immuno-oncology in the pharmaceutical industry: analyzing innovation, investment, and hiring trends


27.


28. 30.


33. 34. 37.


Influx of adoptive cell therapies may be on the horizon


CAR-T landscape set to expand in 2024


Subcutaneous drugs grant a new lease on life to checkpoint inhibitors


Chapter 3: Patient centricity in oncology trials


How patient advocacy can lead to more successful and meaningful clinical trials


Crossing the Divide: A Drug Development Professional’s Experience as a Clinical Trial Participant


39.


Sponsors must take on FDA’s diversity guidance to improve community trust


4 | Clinical Trials in Oncology


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44